Key Highlights

  • Dare Bioscience's indicated pre-market quote of USD 0.50 represents a 16.55% gain on a calculated prior close of USD 0.4290, which places its calculated Market Value near USD 9.8 million.
  • Neuronetics sold new stock to investors at USD 1.60 a share on November 10, 2026, a deal bringing in close to USD 30 million, while the shares now trade indicated at USD 1.43 before the bell.
  • SciSparc's 1-for-9 reverse split took effect on March 4, 2026, and the stock sits indicated 11.62% higher at USD 0.368, with USD 4.4 million of cash reported for the first half.
  • Quanome plans to issue 6,541,236 new shares to QAI Labs in a USD 5.0 million all-stock transaction, and its stock is indicated 11.47% higher at USD 0.3324.

Dare Bioscience (NASDAQ:DARE): Rebound Following Results and a Grant Payment

Early trading has lifted Dare Bioscience to an indicated USD 0.50, roughly 16.55% above a calculated prior close of USD 0.4290. Nothing dated that morning was published, so the advance looks like a continuation of the reaction to the third quarter report released on November 16, 2026. That report put Revenue near USD 48,000, the net loss around USD 3.2 million and cash close to USD 11.5 million, implying a calculated 3.6 quarters of runway at the latest burn rate. A grant installment of USD 851,796 was announced as well at Dare Bioscience, drawn from a funding pact that could ultimately total roughly USD 10.7 million. Sales for fiscal 2025 amounted to USD 1.03 million, while the latest twelve-month stretch shows USD 1.37 million of revenue and a USD 10.99 million shortfall on the bottom line. The DARE to PLAY topical sildenafil cream has prescriptions written across 48 states, and the product is central to the story. It sits with Dare Bioscience alongside a topical sildenafil cream, with prescriptions written across 48 states. Multiplying 19.67 million shares by the quote puts Dare Bioscience at roughly USD 9.8 million of calculated market value, a nano-cap footprint where dilution and thin trading loom large, while the price remains under the USD 1.00 marker linked to Nasdaq minimum bid rules and possible FDA changes to compounding practice add to the risk.

Neuronetics (NASDAQ:STIM): Recovery Following a USD 30 Million Raise

Neuronetics is indicated at USD 1.43 before the bell, a gain of 11.72% over a calculated prior close of USD 1.28, equal to USD 0.15 a share. The quote sits roughly 10.6% beneath the USD 1.60 offering price, a figure derived from the two prices. Coverage located no new statement from Neuronetics dated November 18, 2026. The offering itself placed 18,750,000 shares on November 10, 2026, raising about USD 30 million gross, with an option on a further 2,812,500 shares. Proceeds are earmarked partly to pay down the Perceptive term loan, a Facility that demands at least USD 15 million be prepaid. Third quarter revenue at Neuronetics rose 12.5% to USD 42.0 million, driven by Greenbrook clinic sales of USD 26.2 million and NeuroStar sales of USD 15.8 million. Neuronetics lifted gross Margin to 52.2% from 45.9% while trimming operating costs 13% to USD 21.3 million, and the net loss shrank from USD 9.4 million to USD 1.6 million. Operating Income reached USD 0.5 million, adjusted EBITDA hit USD 1.9 million, and total cash stood at USD 27.9 million, with full-year revenue of USD 160 million to USD 164 million reaffirmed. Dilution, covenant limits and the going-concern language in recent filings are the main hazards.

SciSparc (NASDAQ:SPRC): No Catalyst Against a Backdrop of Dilution

No public catalyst stands out, and SciSparc now shows an indicated USD 0.368, which is 11.62% above a calculated prior close of USD 0.3297, a move of USD 0.0383 on that basis. The shares remain below USD 1.00 and have shed about 96.43% over 52 weeks. Reverse split activity is central here: a 1-for-9 consolidation became effective March 4, 2026, cutting ordinary shares from roughly 5.1 million to around 565,500. SciSparc develops the cannabinoid candidates SCI-110 and SCI-210 and operates an E-commerce arm. Revenue for the first half of 2026 declined 38% to USD 284,000, and the net loss came to USD 6.1 million, with an operating loss of USD 4.9 million against USD 6.0 million a year earlier. At SciSparc, cash rose to USD 4.4 million from USD 1.5 million at year-end 2025, yet the company operated with negative Working Capital of USD 1.4 million, and its accumulated Deficit stands at USD 92.5 million. NeuroThera, a subsidiary, brought in USD 3.8 million, and on a rolling twelve-month view the company reports USD 679,000 of sales with a net deficit of USD 8.22 million, plus USD 2.68 million of borrowings. Filings include a going-concern warning, and convertible notes priced at 90% of the purchase amount point to continued dilution risk for SciSparc.

Quanome Technologies (NASDAQ:QNME): QAI Labs Stake and Going-Concern Exposure

Quanome Technologies is indicated at USD 0.3324 before the open, rising 11.47% against a calculated prior close of USD 0.2982, a calculated gain of USD 0.0342. Multiplying 34,969,416 shares by the quote gives a calculated market Capitalization of roughly USD 11.62 million, a nano-cap figure. No dated announcement surfaced for the day. The most important recent step is an all-stock arrangement signed on November 4, 2026, under which 6,541,236 unregistered shares, about 19% of the stock before issuance, go to QAI Labs for roughly 5% of that company, valued at USD 5.0 million. For the quarter ended September 30, 2026, Quanome Technologies recorded revenue of USD 2,048,083 and a net loss of USD 664,270, a calculated 32.4% of sales. Cash of USD 669,954 sat against USD 8,396,706 of total liabilities and USD 14,855,050 of total assets, a calculated liabilities-to-assets ratio of 56.5%. The subsidiaries of Quanome Technologies, largely based in China, mainly distribute pharmaceutical and medical products. Chief Executive Officer Yang Li framed the transaction as moving another quantum and artificial intelligence strategy into action. A related-party Loan of USD 3,799,980 was drawn in the quarter, and the filing flags going-concern doubt, an accumulated deficit near USD 15.5 million and dilution for existing holders of Quanome Technologies.

Where Things Stand

Four healthcare stocks are trading higher on the morning of November 18, 2026, with no same-day release logged for any of them. Dare Bioscience leads at 16.55%, carrying a calculated market value near USD 9.8 million. Neuronetics is up 11.72% after its USD 30 million offering priced at USD 1.60. SciSparc is up 11.62% at USD 0.368 while going-concern language persists. Quanome Technologies is up 11.47%, supported by USD 669,954 of cash and a calculated market capitalization of about USD 11.62 million. Each name carries different cash, dilution and listing exposure, and early moves can reverse at the regular open. This is not Investment advice.